237 related articles for article (PubMed ID: 35343049)
1. A precision medicine approach to hereditary hemorrhagic telangiectasia and complex vascular anomalies.
Al-Samkari H; Eng W
J Thromb Haemost; 2022 May; 20(5):1077-1088. PubMed ID: 35343049
[TBL] [Abstract][Full Text] [Related]
2. How we approach the use of sirolimus and new agents: Medical therapy to treat vascular anomalies.
Shimano KA; Eng W; Adams DM
Pediatr Blood Cancer; 2022 Aug; 69 Suppl 3():e29603. PubMed ID: 35253343
[TBL] [Abstract][Full Text] [Related]
3. Vascular malformations syndromes: an update.
Martinez-Lopez A; Salvador-Rodriguez L; Montero-Vilchez T; Molina-Leyva A; Tercedor-Sanchez J; Arias-Santiago S
Curr Opin Pediatr; 2019 Dec; 31(6):747-753. PubMed ID: 31693582
[TBL] [Abstract][Full Text] [Related]
4. Selective effects of oral antiangiogenic tyrosine kinase inhibitors on an animal model of hereditary hemorrhagic telangiectasia.
Kim YH; Kim MJ; Choe SW; Sprecher D; Lee YJ; P Oh S
J Thromb Haemost; 2017 Jun; 15(6):1095-1102. PubMed ID: 28339142
[TBL] [Abstract][Full Text] [Related]
5. Association of common candidate variants with vascular malformations and intracranial hemorrhage in hereditary hemorrhagic telangiectasia.
Pawlikowska L; Nelson J; Guo DE; McCulloch CE; Lawton MT; Kim H; Faughnan ME;
Mol Genet Genomic Med; 2018 May; 6(3):350-356. PubMed ID: 29932521
[TBL] [Abstract][Full Text] [Related]
6. The ACVRL1 c.314-35A>G polymorphism is associated with organ vascular malformations in hereditary hemorrhagic telangiectasia patients with ENG mutations, but not in patients with ACVRL1 mutations.
Pawlikowska L; Nelson J; Guo DE; McCulloch CE; Lawton MT; Young WL; Kim H; Faughnan ME;
Am J Med Genet A; 2015 Jun; 167(6):1262-7. PubMed ID: 25847705
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic targeting of vascular malformation in a zebrafish model of hereditary haemorrhagic telangiectasia.
Snodgrass RO; Govindpani K; Plant K; Kugler EC; Doh C; Dawson T; McCormack LE; Arthur HM; Chico TJA
Dis Model Mech; 2023 Apr; 16(4):. PubMed ID: 36861761
[TBL] [Abstract][Full Text] [Related]
8. Correcting Smad1/5/8, mTOR, and VEGFR2 treats pathology in hereditary hemorrhagic telangiectasia models.
Ruiz S; Zhao H; Chandakkar P; Papoin J; Choi H; Nomura-Kitabayashi A; Patel R; Gillen M; Diao L; Chatterjee PK; He M; Al-Abed Y; Wang P; Metz CN; Oh SP; Blanc L; Campagne F; Marambaud P
J Clin Invest; 2020 Feb; 130(2):942-957. PubMed ID: 31689244
[TBL] [Abstract][Full Text] [Related]
9. Future treatments for hereditary hemorrhagic telangiectasia.
Robert F; Desroches-Castan A; Bailly S; Dupuis-Girod S; Feige JJ
Orphanet J Rare Dis; 2020 Jan; 15(1):4. PubMed ID: 31910860
[TBL] [Abstract][Full Text] [Related]
10. Phenotype of CM-AVM2 caused by variants in EPHB4: how much overlap with hereditary hemorrhagic telangiectasia (HHT)?
Wooderchak-Donahue WL; Akay G; Whitehead K; Briggs E; Stevenson DA; O'Fallon B; Velinder M; Farrell A; Shen W; Bedoukian E; Skrabann CM; Antaya RJ; Henderson K; Pollak J; Treat J; Day R; Jacher JE; Hannibal M; Bontempo K; Marth G; Bayrak-Toydemir P; McDonald J
Genet Med; 2019 Sep; 21(9):2007-2014. PubMed ID: 30760892
[TBL] [Abstract][Full Text] [Related]
11. Somatic Mutations in Vascular Malformations of Hereditary Hemorrhagic Telangiectasia Result in Bi-allelic Loss of ENG or ACVRL1.
Snellings DA; Gallione CJ; Clark DS; Vozoris NT; Faughnan ME; Marchuk DA
Am J Hum Genet; 2019 Nov; 105(5):894-906. PubMed ID: 31630786
[TBL] [Abstract][Full Text] [Related]
12. Iron deficiency anemia related to hereditary hemorrhagic telangiectasia: response to treatment with bevacizumab.
Fleagle JM; Bobba RK; Kardinal CG; Freter CE
Am J Med Sci; 2012 Mar; 343(3):249-51. PubMed ID: 22227516
[TBL] [Abstract][Full Text] [Related]
13. Successful therapy with bevacizumab in a case of hereditary hemorrhagic telangiectasia.
Kochanowski J; Sobieszczańska M; Tubek S; Żurek M; Pawełczak J
Hum Vaccin Immunother; 2015; 11(3):680-1. PubMed ID: 25839219
[TBL] [Abstract][Full Text] [Related]
14. [Bevacizumab: a new success in hereditary hemorrhagic telangiectasia].
Bennesser Alaoui H; Lehraiki M; Hamaz S; El Attar N; Fakhreddine N; Serraj K
Rev Med Interne; 2015 Sep; 36(9):623-5. PubMed ID: 25595875
[TBL] [Abstract][Full Text] [Related]
15. Multidisciplinary coordinated care of hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu disease).
Alkhalid Y; Darji Z; Shenkar R; Clancy M; Dyamenahalli U; Awad IA;
Vasc Med; 2023 Apr; 28(2):153-165. PubMed ID: 36890671
[TBL] [Abstract][Full Text] [Related]
16. Prevalence and characteristics of brain arteriovenous malformations in hereditary hemorrhagic telangiectasia: a systematic review and meta-analysis.
Brinjikji W; Iyer VN; Wood CP; Lanzino G
J Neurosurg; 2017 Aug; 127(2):302-310. PubMed ID: 27767404
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA-132-3p, Downregulated in Myeloid Angiogenic Cells from Hereditary Hemorrhagic Telangiectasia Patients, Is Enriched in the TGFβ and PI3K/AKT Signalling Pathways.
Cannavicci A; Zhang Q; Faughnan ME; Kutryk MJB
Genes (Basel); 2022 Apr; 13(4):. PubMed ID: 35456471
[TBL] [Abstract][Full Text] [Related]
18. Blessing for the bleeder: bevacizumab in hereditary hemorrhagic telangiectasia.
Epperla N; Hocking W
Clin Med Res; 2015 Mar; 13(1):32-5. PubMed ID: 24667223
[TBL] [Abstract][Full Text] [Related]
19. ALK1 Loss Results in Vascular Hyperplasia in Mice and Humans Through PI3K Activation.
Alsina-Sanchís E; García-Ibáñez Y; Figueiredo AM; Riera-Domingo C; Figueras A; Matias-Guiu X; Casanovas O; Botella LM; Pujana MA; Riera-Mestre A; Graupera M; Viñals F
Arterioscler Thromb Vasc Biol; 2018 May; 38(5):1216-1229. PubMed ID: 29449337
[TBL] [Abstract][Full Text] [Related]
20. Pericytes in Hereditary Hemorrhagic Telangiectasia.
Galaris G; Thalgott JH; Lebrin FPG
Adv Exp Med Biol; 2019; 1147():215-246. PubMed ID: 31147880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
